Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials

Hepatobiliary and Pancreatic Diseases International

Volumn 16, Issue 3, 2017, Pages 236-244

  Jin, Shui Fang ^a   Fan, Zhao Kun ^a   Pan, Lei ^a   Jin, Li Ming ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

chemotherapy; cisplatin; gemcitabine; meta analysis; pancreatic cancer; S 1

Indexed keywords

CISPLATIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEUKOPENIA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; ADULT; AGED; ANALOGS AND DERIVATIVES; CHI SQUARE DISTRIBUTION; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; MORTALITY; ODDS RATIO; PANCREAS TUMOR; PATHOLOGY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85020854393     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(17)60022-5     Document Type: Article

References (29)

1. Jemal, A, Siegel, R, Xu, J, Ward, E, Cancer statistics, 2010. CA Cancer J Clin 60 (2010), 277–300.
2. Malvezzi, M, Bertuccio, P, Levi, F, La Vecchia, C, Negri, E, European cancer mortality predictions for the year 2013. Ann Oncol 24 (2013), 792–800.
3. Siegel, R, Ma, J, Zou, Z, Jemal, A, Cancer statistics, 2014. CA Cancer J Clin 64 (2014), 9–29.
4. Kamisawa, T, Wood, LD, Itoi, T, Takaori, K, Pancreatic cancer. Lancet 388 (2016), 73–85.
5. Squadroni, M, Fazio, N, Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci 14 (2010), 386–394.
6. Neoptolemos, JP, Stocken, DD, Bassi, C, Ghaneh, P, Cunningham, D, Goldstein, D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304 (2010), 1073–1081.
7. Reni, M, Cereda, S, Rognone, A, Belli, C, Ghidini, M, Longoni, S, et al. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 69 (2012), 115–123.
8. Ghaneh, P, Smith, R, Tudor-Smith, C, Raraty, M, Neoptolemos, JP, Neoadjuvant and adjuvant strategies for pancreatic cancer. Eur J Surg Oncol 34 (2008), 297–305.
9. Katz, MH, Fleming, JB, Lee, JE, Pisters, PW, Current status of adjuvant therapy for pancreatic cancer. Oncologist 15 (2010), 1205–1213.
10. Petrelli, F, Coinu, A, Borgonovo, K, Cabiddu, M, Barni, S, Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials. Hepatobiliary Pancreat Dis Int 14 (2015), 124–131.
11. Heinemann, V, Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 29 (2002), 9–16.
12. Cao, C, Kuang, M, Xu, W, Zhang, X, Chen, J, Tang, C, Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer. Jpn J Clin Oncol 45 (2015), 1122–1130.
13. Inal, A, Kos, FT, Algin, E, Yildiz, R, Dikiltas, M, Unek, IT, et al. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. Neoplasma 59 (2012), 297–301.
14. Higgins, JP, Thompson, SG, Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
15. Chao, Y, Wu, CY, Wang, JP, Lee, RC, Lee, WP, Li, CP, A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Cancer Chemother Pharmacol 72 (2013), 637–642.
16. Colucci, G, Giuliani, F, Gebbia, V, Biglietto, M, Rabitti, P, Uomo, G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94 (2002), 902–910.
17. Colucci, G, Labianca, R, Di Costanzo, F, Gebbia, V, Cartenì, G, Massidda, B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28 (2010), 1645–1651.
18. Heinemann, V, Quietzsch, D, Gieseler, F, Gonnermann, M, Schönekös, H, Rost, A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24 (2006), 3946–3952.
19. Nakai, Y, Isayama, H, Sasaki, T, Sasahira, N, Tsujino, T, Toda, N, et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 106 (2012), 1934–1939.
20. Ozaka, M, Matsumura, Y, Ishii, H, Omuro, Y, Itoi, T, Mouri, H, et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol 69 (2012), 1197–1204.
21. Sudo, K, Ishihara, T, Hirata, N, Ozawa, F, Ohshima, T, Azemoto, R, et al. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemother Pharmacol 73 (2014), 389–396.
22. Ueno, H, Ioka, T, Ikeda, M, Ohkawa, S, Yanagimoto, H, Boku, N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31 (2013), 1640–1648.
23. Wang, X, Ni, Q, Jin, M, Li, Z, Wu, Y, Zhao, Y, et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua Zhong Liu Za Zhi 24 (2002), 404–407.
24. Spadi, R, Brusa, F, Ponzetti, A, Chiappino, I, Birocco, N, Ciuffreda, L, et al. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol 7 (2016), 27–43.
25. Hess, V, Pratsch, S, Potthast, S, Lee, L, Winterhalder, R, Widmer, L, et al. Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Ann Oncol 21 (2010), 2390–2395.
26. Rougier, P, Riess, H, Manges, R, Karasek, P, Humblet, Y, Barone, C, et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 49 (2013), 2633–2642.
27. Zhao, YP, Interpretation of the Chinese edition of NCCN Clinical Practice Guidelines in Oncology-Pancreatic Adenocarcinoma Guideline 2011. Zhonghua Wai Ke Za Zhi 49 (2011), 771–773.
28. Banu, E, Banu, A, Fodor, A, Landi, B, Rougier, P, Chatellier, G, et al. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging 24 (2007), 865–879.
29. Ciliberto, D, Botta, C, Correale, P, Rossi, M, Caraglia, M, Tassone, P, et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 49 (2013), 593–603.